|Bid||95.10 x 1100|
|Ask||95.24 x 1000|
|Day's Range||93.45 - 96.94|
|52 Week Range||72.14 - 136.26|
|Beta (5Y Monthly)||1.14|
|PE Ratio (TTM)||98.77|
|Earnings Date||Feb 02, 2021 - Feb 08, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Dec 29, 1995|
|1y Target Est||126.43|
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Neurocrine Biosciences management will present at the following investor conferences:
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the Company has entered into separate, privately negotiated transactions (the "Agreements") with certain holders of its existing 2.25% Convertible Senior Notes due 2024 (the "2024 Notes") to repurchase approximately $83 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of an amount of cash estimated to be the sum of (i) approximately $110 million based on the Company's November 18, 2020 closing stock price of $86.91 per share, (ii) an amount based in part on the daily volume-weighted average prices per share of the Company's common stock during a five-trading day pricing period following execution of the Agreements and (iii) accrued and unpaid interest. The 2024 Notes repurchases are expected to close on December 2, 2020, subject to customary closing conditions. Such repurchases of the 2024 Notes could affect the market price of the Company's common stock.
Last week, you might have seen that Neurocrine Biosciences, Inc. (NASDAQ:NBIX) released its third-quarter result to...